| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | SOCS1 |
| Uniprot No | O15524 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-211aa |
| 氨基酸序列 | MVAHNQVAADNAVSTAAEPRRRPEPSSSSSSSPAAPARPRPCPAVPAPAP GDTHFRTFRSHADYRRITRASALLDACGFYWGPLSVHGAHERLRAEPVGT FLVRDSRQRNCFFALSVKMASGPTSIRVHFQAGRFHLDGSRESFDCLFEL LEHYVAAPRRMLGAPLRQRRVRPLQELCRQRIVATVGRENLARIPLNPVL RDYLSSFPFQI |
| 预测分子量 | 28 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3条关于SOCS1重组蛋白的参考文献示例(注：内容为模拟概括，非真实文献)：
---
1. **"Structural insights into SOCS1-mediated JAK2 degradation"**
*作者：Yoshimura A., et al. (2007)*
摘要：通过重组SOCS1蛋白与JAK2激酶的共结晶研究，揭示了SOCS1通过SH2结构域特异性结合磷酸化JAK2.并招募Elongin B/C-Cullin复合物，介导泛素化降解的分子机制。
2. **"Recombinant SOCS1 protein attenuates LPS-induced inflammation in macrophages"**
*作者：Li J., et al. (2012)*
摘要：体外实验表明，纯化的重组SOCS1蛋白可抑制LPS激活的巨噬细胞中NF-κB和STAT1信号通路，降低TNF-α和IL-6分泌，证实其抗炎潜力。
3. **"SOCS1 recombinant protein enhances antitumor immunity by modulating T cell exhaustion"**
*作者：Wang Y., et al. (2020)*
摘要：在小鼠模型中，注射重组SOCS1蛋白通过阻断PD-1/STAT1信号通路，逆转CD8+ T细胞耗竭，显著抑制黑色素瘤生长，为肿瘤免疫治疗提供新策略。
---
*注：以上文献为示例性质，实际研究中请通过PubMed或Web of Science核对真实文献。*
SOCS1 (Suppressor of Cytokine Signaling 1) is a critical regulatory protein involved in controlling cytokine-mediated signaling pathways, particularly the JAK-STAT (Janus kinase-signal transducer and activator of transcription) cascade. Discovered in 1997. it belongs to the SOCS family of intracellular proteins that function as negative feedback inhibitors to maintain immune homeostasis and prevent excessive inflammation. Structurally, SOCS1 contains a central SH2 (Src homology 2) domain that recognizes phosphorylated tyrosine residues on activated cytokine receptors or JAK kinases, and a C-terminal SOCS box that mediates protein degradation via ubiquitin-proteasome pathways.
Recombinant SOCS1 protein is engineered through molecular cloning techniques, typically expressed in bacterial (e.g., *E. coli*) or mammalian cell systems to ensure proper folding and post-translational modifications. This engineered protein retains the functional domains required for binding to phosphorylated JAK kinases and targeting them for degradation, making it a valuable tool for studying cytokine signaling regulation *in vitro*. Researchers use recombinant SOCS1 to investigate mechanisms of immune disorders, cancer progression (where SOCS1 often acts as a tumor suppressor), and viral immune evasion strategies. Its therapeutic potential is being explored in autoimmune diseases, chronic inflammation, and cytokine storm syndromes, where excessive signaling contributes to pathology. Recent studies also highlight its role in metabolic regulation and T-cell differentiation, expanding its relevance beyond classical immune pathways. Quality validation typically includes Western blotting, ELISA-based activity assays, and functional tests in cell models to confirm inhibitory effects on STAT phosphorylation.
×
